Table 4.
The cytotoxic activity of derivatives 3–4, 5a–k, 6a–h and cisplatin against tested cell lines: T47D (human ductal carcinoma), MCF-7 (human adenocarcinoma), SNB-19 (glioblastoma), Colo-829 (human malignant melanoma), and C-32 (human amelanotic melanoma).
| Compound | Human Cell Line /IC50 ± SD [μM] | ||||
|---|---|---|---|---|---|
| T47D | MCF-7 | SNB-19 | Colo-829 | C-32 | |
| Betulin 1 | Neg | Neg | 17.7 ± 1.2 | 15.3 ± 2.2 | Neg |
| 3 | 110.8 ± 0.9 | 102.1 ± 1.4 | 4.2 ± 0.3 | 1.7 ± 0.08 | 16.7 ± 0.8 |
| 4 | Neg | Neg | 13.1 ± 1.3 | 9.7 ± 1.5 | 121.2 ± 4.1 |
| 5a | 10.5 ± 0.09 | 58.8 ± 1.5 | 96.2 ± 1.2 | 78.5 ± 8.3 | Neg |
| 5b | 8.5 ± 0.02 | Neg | 66.1 ± 0.7 | 129.2 ± 7.7 | Neg |
| 5c | 1.4 ± 0.01 | Neg | 0.70 ± 0.08 | 9.7 ± 0.1 | Neg |
| 5d | 52.5 ± 1.4 | Neg | 13.0 ± 0.09 | 100.0 ± 5.5 | Neg |
| 5e | Neg | Neg | Neg | 35.1 ± 6.2 | 75.2 ± 3.7 |
| 5f | Neg | Neg | Neg | 109.5 ± 7.2 | Neg |
| 5g | 135.2 ± 2.6 | Neg | 92.3 ± 0.9 | 11.4 ± 0.2 | Neg |
| 5h | 1.3 ± 0.05 | 15.5 ± 1.1 | 9.9 ± 0.7 | 6.2 ± 0.6 | 80.3 ± 5.8 |
| 5i | 3.63 ± 0.3 | 6.94 ± 0.8 | 0.9 ± 0.03 | 0.6 ± 0.13 | 7.9 ± 0.9 |
| 5j | Neg | Neg | Neg | 3.3 ± 1.1 | Neg |
| 5k | 7.2 ± 0.2 | 37.2 ± 0.7 | 6.3 ± 0.9 | 8.7 ± 0.5 | 46.9 ± 2.5 |
| 6a | Neg | Neg | 24.4 ± 1.3 | 80.7 ± 1.8 | Neg |
| 6b | 0.05 ± 0.01 | 0.09 ± 0.01 | 0.08 ± 0.01 | Neg | Neg |
| 6c | 1.1 ± 0.01 | 60.7 ± 0.6 | 0.06 ± 0.01 | Neg | Neg |
| 6d | 0.9 ± 0.05 | 0.9 ± 0.08 | 0.5 ± 0.02 | 102.6 ± 4.7 | 100.4 ± 2.8 |
| 6e | Neg | Neg | Neg | Neg | Neg |
| 6f | Neg | Neg | Neg | Neg | Neg |
| 6g | Neg | Neg | Neg | 97.6±3.3 | Neg |
| 6h | 62.4 ± 1.1 | 11.7 ± 1.2 | 68.3 ± 0.9 | 6.5 ± 1.0 | 9.1 ± 0.2 |
| Cisplatin | 24.9 ± 1.1 | 5.5 ± 1.0 | 2.3 ± 0.05 | 16.8 ± 1.7 | 12.3 ± 2.1 |
Neg—negative in the concentration used.